Dicot Pharma AB (STO:DICOT)
Sweden · Delayed Price · Currency is SEK 0.2170
-0.0022 (-1.00%)
Nov 4, 2026, 5:25 PM CET
Dicot Pharma AB Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
4
Market Cap
752.71M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioGaia AB | 1.65B |
| EQL Pharma AB | 432.35M |
| Enzymatica AB | 51.49M |
| Cinclus Pharma Holding AB | 35.18M |
| Nanexa AB | 33.86M |
| Moberg Pharma AB | 16.76M |
| Orexo AB | 12.50M |
| Enorama Pharma AB | 1.45M |
Dicot Pharma AB News
- 7 days ago - Dicot Pharma AB Quarterly report: Q3 2026 - Filings
- 2 months ago - Dicot Pharma AB Quarterly report: Q2 2026 - Filings
- 5 months ago - Dicot Pharma AB Press release: Investor update - Filings
- 6 months ago - Dicot Pharma AB Quarterly report: Q1 2026 - Filings
- 8 months ago - Dicot Pharma AB Annual report: Q4 2025 - Filings
- 8 months ago - Dicot Pharma AB Quarterly report: Q4 2025 - Filings